MARKET

ADVM

ADVM

Adverum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.63
+0.07
+0.73%
Opening 10:34 04/23 EDT
OPEN
9.56
PREV CLOSE
9.56
HIGH
9.70
LOW
9.52
VOLUME
38.22K
TURNOVER
--
52 WEEK HIGH
26.98
52 WEEK LOW
8.58
MARKET CAP
943.04M
P/E (TTM)
-7.0169
1D
5D
1M
3M
1Y
5Y
The Sonic Fund II, L.P. Issues Presentation Detailing Compelling Case for Immediate Board Upgrade at Adverum Biotechnologies, Inc.
--Contrary to Adverum's Specious Arguments, Sonic Is Not Seeking to Gain Control of the Board - It Is Instead Seeking to Add Independent Individuals with Essential Experience and to Prevent Further Entrenchment
BusinessWire · 17h ago
Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation
Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Adveru...
GlobeNewswire · 18h ago
Adverum Biotechnologies (NASDAQ:ADVM) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 1d ago
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
Adverum Slate Background Adverum Slate Background Adverum Board Matrix Adverum Board Matrix Sonic’s Nominees Lack Experience and Qualifications to Advance Adverum’s Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy Urges Sto...
GlobeNewswire · 2d ago
BRIEF-The Sonic Fund Ii, L.P. Files Definitive Proxy Statement And Sends Letter To Stockholders Of Adverum Biotechnologies, Inc.
reuters.com · 3d ago
The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies, Inc.
--Adverum Is Abusing the Corporate Machinery to Entrench Incumbent Directors and Disenfranchise Stockholders
BusinessWire · 3d ago
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical...
GlobeNewswire · 04/16 13:05
Adverum Biotechnologies To Present New Data From OPTIC Trial Of ADVM-022 Intravitreal Gene Therapy For Wet AMD At Association For Research In Vision And Ophthalmology 2021 On May 3
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 -- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM
Benzinga · 04/16 12:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADVM. Analyze the recent business situations of Adverum through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADVM stock price target is 24.89 with a high estimate of 30.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 209
Institutional Holdings: 104.84M
% Owned: 107.06%
Shares Outstanding: 97.93M
TypeInstitutionsShares
Increased
53
8.49M
New
24
1.17M
Decreased
51
7.40M
Sold Out
29
3.05M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.22%
Pharmaceuticals & Medical Research
+0.23%
Key Executives
Chairman/Independent Director
Patrick Machado
Chairman/Independent Director
C. Patrick Machado
President/Chief Financial Officer
Leone Patterson
Chief Executive Officer/Director
Laurent Fischer
Chief Technology Officer
Angela Thedinga
Vice President
Heikki Jouttijarvi
Vice President
Thomas Kochy
Vice President
Christopher Morrison
Vice President
Anand Reddi
Vice President
Bill Tan
Other
Christopher DeRespino
Other
Peter Soparkar
Director
Mehdi Gasmi
Independent Director
Mark Lupher
Independent Director
James Scopa
Independent Director
Richard Spivey
Independent Director
Dawn Svoronos
Independent Director
Reed Tuckson
Independent Director
Scott Whitcup
Independent Director
Thomas Woiwode
No Data
  • All
  • Financials
  • Insiders
More
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.

Webull offers kinds of Adverum Biotechnologies Inc stock information, including NASDAQ:ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.